Ophthalmology

Measures of inflammation can predict treatment outcomes for patients

An updated PDS procedure reduces complications.

Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

Retinal imaging tests are providing material to train and test decision support systems.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Novel therapies are shifting the paradigm in care of retinal diseases

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

Investigators offer insight on how patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

Community support and research continue to boost treatment in children

Studies are uncovering a range of potential treatment options for disorders

How a combined ophthalmology/rheumatology uveitis clinic collaborates to monitor systemic disease activity and tolerance to systemic therapy

Worldwide increase in technologies for ophthalmic use is dramatic

Fluocinolone acetonide implant for DME benefits visual acuity

For ophthalmologists, the interactive landscape of surgical visualization, including 3D digital surgery, robotics, and an OCT-enriched surgical theater, is leading to new opportunities.

Numerous studies will be completed during the next few years, and many new studies are being developed.

Studying zebrafish helps unravel mysteries of photoreceptor regeneration

Short FLIO flecks may appear before changes are seen on other imaging modalities, including OCT.

This novel intravitreal gene therapy may also hold potential for the treatment of diabetic macular edema.

Studies highlight the need for specialists and training programs focusing on the disease.